Arbutus Biopharma Corp (NASDAQ: ABUS) kicked off on Tuesday, up 6.48% from the previous trading day, before settling in for the closing price of $3.86. Over the past 52 weeks, ABUS has traded in a range of $1.69-$4.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 55.33%. While this was happening, its average annual earnings per share was recorded 12.27%. With a float of $146.67 million, this company’s outstanding shares have now reached $169.87 million.
Considering the fact that the conglomerate employs 73 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 85.7%, operating margin of -821.32%, and the pretax margin is -766.2%.
Arbutus Biopharma Corp (ABUS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arbutus Biopharma Corp is 22.31%, while institutional ownership is 51.24%. The most recent insider transaction that took place on Aug 14 ’24, was worth 32,637. In this transaction Director of this company sold 8,846 shares at a rate of $3.69, taking the stock ownership to the 46,069 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Medical Officer sold 4,358 for $2.31, making the entire transaction worth $10,078. This insider now owns 125,542 shares in total.
Arbutus Biopharma Corp (ABUS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 12.27% per share during the next fiscal year.
Arbutus Biopharma Corp (NASDAQ: ABUS) Trading Performance Indicators
Take a look at Arbutus Biopharma Corp’s (ABUS) current performance indicators. Last quarter, stock had a quick ratio of 6.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.35 in one year’s time.
Technical Analysis of Arbutus Biopharma Corp (ABUS)
Compared to the last year’s volume of 1.13 million, its volume of 0.67 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 76.50%. Additionally, its Average True Range was 0.15.
During the past 100 days, Arbutus Biopharma Corp’s (ABUS) raw stochastic average was set at 66.02%, which indicates a significant decrease from 97.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.92% in the past 14 days, which was lower than the 42.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.95, while its 200-day Moving Average is $3.19. Nevertheless, the first resistance level for the watch stands at $4.19 in the near term. At $4.27, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.42. If the price goes on to break the first support level at $3.96, it is likely to go to the next support level at $3.81. Should the price break the second support level, the third support level stands at $3.73.
Arbutus Biopharma Corp (NASDAQ: ABUS) Key Stats
The company with the Market Capitalisation of 775.89 million has total of 188,717K Shares Outstanding. Its annual sales at the moment are 18,140 K in contrast with the sum of -72,850 K annual income. Company’s last quarter sales were recorded 1,730 K and last quarter income was -19,800 K.
